Welcome to our dedicated page for Clearpoint Neuro SEC filings (Ticker: CLPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ClearPoint Neuro, Inc. (Nasdaq: CLPT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ClearPoint Neuro is a medical device company that develops device, cell, and gene therapy-enabling technologies for precise navigation to the brain and spine, and its filings offer detailed insight into this business.
Here you can review current and historical Forms 8-K, which ClearPoint Neuro uses to report material events such as preliminary unaudited financial results and significant transactions. For example, the company has filed 8-Ks announcing quarterly and annual financial results, as well as the completion of its acquisition of IRRAS Holdings, Inc., a transaction that expands ClearPoint Neuro’s presence in intracranial fluid management and neurocritical care.
Investors can also use this page to locate annual reports on Form 10-K and quarterly reports on Form 10-Q when available, which typically contain information on revenue by category, operating expenses, and risk factors relevant to ClearPoint Neuro’s neurosurgical navigation, laser therapy, biologics and drug delivery, and intracranial fluid management activities. In addition, registration statements and related documents may describe share issuances connected to mergers or financing arrangements, such as the common stock issued in connection with the IRRAS merger.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of new disclosures. Real-time updates from EDGAR ensure that new CLPT filings, including Forms 4 for insider transactions and proxy materials related to governance and compensation, are available as they are posted. This page is intended as a central resource for analyzing ClearPoint Neuro’s regulatory history, capital structure changes, and material corporate events through its official SEC filings.
ClearPoint Neuro, Inc. reported that Chief Operating Officer Sabra Mazin acquired 36,818 restricted stock units (RSUs) of company stock as a compensation award. Each RSU represents a contingent right to receive one share of CLPT common stock if vesting conditions are met.
The award vests over three years: 20% of the RSUs on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029. After this grant, Mazin directly holds 36,818 RSUs, aligning part of her compensation with the company’s future performance.
STIGALL L. JEREMY reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. Chief Business Officer L. Jeremy Stigall received a grant of 51,546 restricted stock units of ClearPoint Neuro common stock. Each unit represents the right to receive one share of CLPT common stock at vesting. The award vests over three years: 20% of the units on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning a substantial portion of his compensation with the company’s long-term performance.
D'Alessandro Danilo reported acquisition or exercise transactions in this Form 4 filing.
ClearPoint Neuro, Inc. reported that Chief Financial Officer Danilo D'Alessandro received a grant of 66,273 restricted stock units. Each unit represents a contingent right to one share of CLPT common stock. The units vest 20% on February 17, 2027, 40% on February 17, 2028, and 40% on February 17, 2029.
ClearPoint Neuro, Inc. reported that CEO and President Joseph Burnett acquired a grant of 147,275 restricted stock units. Each unit represents a contingent right to receive one share of CLPT common stock.
The restricted stock units vest over three years: 20% of the total shares on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029, aligning the award with multi-year executive retention and performance incentives.
ClearPoint Neuro filed an amended current report to add detailed financial information for its acquisition of IRRAS Holdings, Inc. The 8-K/A supplies IRRAS’s audited 2024 financial statements, unaudited 2025 interim results, and unaudited pro forma combined financials showing how the two businesses would look if reported together.
The company emphasizes that these pro forma figures are for informational purposes only and do not represent actual historical results or forecasts of future performance after the acquisition.
Bigger Capital Fund LP and related entities filed an amended Schedule 13G reporting their beneficial ownership of ClearPoint Neuro, Inc. common stock as of February 4, 2026. Bigger Capital and its general partner Bigger Capital Fund GP, LLC report beneficial ownership of 1,333,155 shares, or about 4.69% of the outstanding stock.
District 2 Capital Fund LP and its affiliated entities report beneficial ownership of 337,696 shares, or about 1.19%. Michael Bigger may be deemed to beneficially own about 7.8% of the common stock, including interests attributed through these funds and family holdings. The percentages are based on 28,423,308 shares outstanding as of October 27, 2025, and the filers certify the holdings are not for the purpose of changing or influencing control of ClearPoint Neuro.
ClearPoint Neuro, Inc. insider activity: a trust associated with CEO and President Joseph Burnett sold 2,943 shares of ClearPoint Neuro common stock on 01/26/2026 at a weighted average price of
After this sale, the Joseph M. Burnett Trust held 214,116 shares indirectly for Mr. Burnett, and he also held 11,565 shares directly. The sale price range was from
A holder of CLPT common stock filed a notice to sell 2,943 shares under Rule 144. The shares are common stock to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $46,146.24, and an approximate sale date of 01/26/2026 on the NASDAQ market. These 2,943 shares were acquired on 08/20/2023 as restricted stock units from the issuer, matching the amount now planned for sale. The filing notes that a related 10b5-1 plan already led to a prior sale of 20,000 common shares on 01/09/2026 for $322,404 in gross proceeds, and states that total common shares outstanding are 28,423,308.
ClearPoint Neuro, Inc. has filed a resale prospectus covering up to 1,312,570 shares of its common stock that may be sold from time to time by former IRRAS Holdings, Inc. stockholders. ClearPoint is not selling shares in this offering and will receive no proceeds from any sales.
The registered shares were or will be issued as part of ClearPoint’s November 20, 2025 acquisition of IRRAS, a neurocritical care medical technology company. Consideration for the merger included $5,000,000 in cash and 1,119,404 ClearPoint shares, plus potential earnout payments. The 1,312,570 registered shares consist of 1,109,401 merger shares plus up to 203,169 holdback shares that may be released if no post-closing adjustments or indemnity claims reduce them.
ClearPoint is a commercial-stage medical device company focused on minimally invasive neurosurgery, including its ClearPoint Navigation System, operating-room focused SmartFrame platforms, and the ClearPoint Prism Neuro Laser Therapy System. Its biologics and drug delivery partnerships support more than 60 gene and cell therapy programs targeting direct delivery into the brain.